Cross-source evidence timeline

Carfilzomib research timeline

Follow 62 selected, directly cited source records from April 27, 2012 through November 16, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

62Selected records
10Source years
3Evidence lanes
November 16, 2026Latest source date

Source year

2026

34 records
  1. Clinical trials

    ClinicalTrials.gov record NCT07715903↗

    PeptideScanner retained ClinicalTrials.gov record NCT07715903 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  2. Literature metadata

    Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study.↗

    PubMed lists PMID 40397818 in Leukemia & lymphoma as Journal Article, Clinical Trial, Phase II, Multicenter Study, Clinical Trial, Phase I, with publication-date metadata of 2025-05-21 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT03606577↗

    PeptideScanner retained ClinicalTrials.gov record NCT03606577 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT06152575↗

    PeptideScanner retained ClinicalTrials.gov record NCT06152575 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT07555938↗

    PeptideScanner retained ClinicalTrials.gov record NCT07555938 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  6. Literature metadata

    Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myel…↗

    PubMed lists PMID 36529145 in The Lancet. Haematology as Clinical Trial, Phase II, Equivalence Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-12-15 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT05497804↗

    PeptideScanner retained ClinicalTrials.gov record NCT05497804 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  8. Literature metadata

    Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis.↗

    PubMed lists PMID 35578151 in International journal of hematology as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-05-17 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Carfilzomib, pomalidomide, and dexamethasone for multiple myeloma after carfilzomib, lenalidomide, and dexamethasone.↗

    PubMed lists PMID 41134506 in International journal of hematology as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2025-10-24 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT04430894↗

    PeptideScanner retained ClinicalTrials.gov record NCT04430894 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT04925193↗

    PeptideScanner retained ClinicalTrials.gov record NCT04925193 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  12. Clinical trials

    ClinicalTrials.gov record NCT01559935↗

    PeptideScanner retained ClinicalTrials.gov record NCT01559935 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  13. Literature metadata

    Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.↗

    PubMed lists PMID 34647444 in Haematologica as Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-06-01 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  14. Literature metadata

    Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.↗

    PubMed lists PMID 41719502 in Blood advances as Journal Article, Clinical Trial, Phase II, Clinical Trial, Phase I, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  15. Clinical trials

    ClinicalTrials.gov record NCT04756401↗

    PeptideScanner retained ClinicalTrials.gov record NCT04756401 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  16. Literature metadata

    Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.↗

    PubMed lists PMID 41942646 in Nature medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, with publication-date metadata of 2026-04-06 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  17. Regulatory

    Drugs@FDA application ANDA209526↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 209526 with status AP dated 2026-07-20, and names carfilzomib among the application record's active ingredients.↗

  18. Clinical trials

    ClinicalTrials.gov record NCT03290950↗

    PeptideScanner retained ClinicalTrials.gov record NCT03290950 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-05-29, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  19. Clinical trials

    ClinicalTrials.gov record NCT03934684↗

    PeptideScanner retained ClinicalTrials.gov record NCT03934684 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  20. Clinical trials

    ClinicalTrials.gov record NCT01816971↗

    PeptideScanner retained ClinicalTrials.gov record NCT01816971 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  21. Clinical trials

    ClinicalTrials.gov record NCT01813227↗

    PeptideScanner retained ClinicalTrials.gov record NCT01813227 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-04-03, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  22. Literature metadata

    Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.↗

    PubMed lists PMID 37717583 in The Lancet. Oncology as Journal Article, Multicenter Study, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-09-14 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  23. Clinical trials

    ClinicalTrials.gov record NCT02773030↗

    PeptideScanner retained ClinicalTrials.gov record NCT02773030 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  24. Clinical trials

    ClinicalTrials.gov record NCT01572480↗

    PeptideScanner retained ClinicalTrials.gov record NCT01572480 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-03-10, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  25. Clinical trials

    ClinicalTrials.gov record NCT03275285↗

    PeptideScanner retained ClinicalTrials.gov record NCT03275285 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-02-09, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  26. Literature metadata

    Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study.↗

    PubMed lists PMID 36073950 in Japanese journal of clinical oncology as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-12-05 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  27. Literature metadata

    Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation.↗

    PubMed lists PMID 36372355 in Transplantation and cellular therapy as Randomized Controlled Trial, Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-11-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  28. Literature metadata

    Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL.↗

    PubMed lists PMID 36375132 in Blood advances as Clinical Trial, Phase I, Journal Article, with publication-date metadata of 2023-04-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  29. Literature metadata

    Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a r…↗

    PubMed lists PMID 36642080 in The Lancet. Oncology as Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-01-12 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  30. Literature metadata

    Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.↗

    PubMed lists PMID 36763537 in Blood advances as Clinical Trial, Phase II, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-10-10 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  31. Literature metadata

    Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis.↗

    PubMed lists PMID 37479547 in Clinical lymphoma, myeloma & leukemia as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-07-03 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  32. Literature metadata

    Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell L…↗

    PubMed lists PMID 37632592 in Targeted oncology as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-08-26 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  33. Literature metadata

    Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomi…↗

    PubMed lists PMID 37691005 in British journal of haematology as Clinical Trial, Phase III, Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-09-10 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  34. Clinical trials

    ClinicalTrials.gov record NCT02969837↗

    PeptideScanner retained ClinicalTrials.gov record NCT02969837 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-01-16, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

Source year

2025

9 records
  1. Clinical trials

    ClinicalTrials.gov record NCT02937571↗

    PeptideScanner retained ClinicalTrials.gov record NCT02937571 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  2. Literature metadata

    Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myeloma.↗

    PubMed lists PMID 40672881 in HemaSphere as Journal Article, Review, with publication-date metadata of 2025-07-16 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT04191616↗

    PeptideScanner retained ClinicalTrials.gov record NCT04191616 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-09-04, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  4. Literature metadata

    Health-Related Quality of Life During Carfilzomib-Lenalidomide-Dexamethasone Consolidation: Findings From the Multiple Myeloma CONPET Study.↗

    PubMed lists PMID 39638553 in European journal of haematology as Clinical Trial, Phase II, Journal Article, Multicenter Study, with publication-date metadata of 2024-12-05 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.↗

    PubMed lists PMID 39576965 in Blood advances as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2025-02-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT03158688↗

    PeptideScanner retained ClinicalTrials.gov record NCT03158688 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-05-09, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT03412565↗

    PeptideScanner retained ClinicalTrials.gov record NCT03412565 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-04-29, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  8. Literature metadata

    Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management.↗

    PubMed lists PMID 40213696 in Frontiers in pharmacology as Journal Article, Review, with publication-date metadata of 2025-03-27 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi.↗

    PubMed lists PMID 38938122 in British journal of haematology as Journal Article, Clinical Trial, Phase II, Multicenter Study, with publication-date metadata of 2024-06-28 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2024

4 records
  1. Literature metadata

    Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.↗

    PubMed lists PMID 38811560 in Blood cancer journal as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-05-29 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis.↗

    PubMed lists PMID 37584290 in Haematologica as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-02-01 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide al…↗

    PubMed lists PMID 38747414 in Polish archives of internal medicine as Journal Article, Clinical Trial, Phase III, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-05-14 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT03859427↗

    PeptideScanner retained ClinicalTrials.gov record NCT03859427 at 2026-11-16T17:39:29.005Z. Its registry update date was 2024-08-13, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

Source year

2022

6 records
  1. Clinical trials

    ClinicalTrials.gov record NCT01568866↗

    PeptideScanner retained ClinicalTrials.gov record NCT01568866 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-11-14, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT03416374↗

    PeptideScanner retained ClinicalTrials.gov record NCT03416374 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-27, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT02412878↗

    PeptideScanner retained ClinicalTrials.gov record NCT02412878 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-23, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT01080391↗

    PeptideScanner retained ClinicalTrials.gov record NCT01080391 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-21, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT03029234↗

    PeptideScanner retained ClinicalTrials.gov record NCT03029234 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-05-25, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

  6. Literature metadata

    Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with…↗

    PubMed lists PMID 34774221 in The Lancet. Oncology as Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-11-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2021

1 record
  1. Regulatory

    Drugs@FDA application ANDA209330↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 209330 with status AP dated 2021-06-11, and names carfilzomib among the application record's active ingredients.↗

Source year

2020

2 records
  1. Regulatory

    Drugs@FDA application ANDA211185↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 211185 with status AP dated 2020-03-20, and names carfilzomib among the application record's active ingredients.↗

  2. Regulatory

    Drugs@FDA application ANDA209425↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 209425 with status AP dated 2020-03-16, and names carfilzomib among the application record's active ingredients.↗

Source year

2019

2 records
  1. Regulatory

    Drugs@FDA application ANDA209422↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 209422 with status AP dated 2019-09-09, and names carfilzomib among the application record's active ingredients.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT01818752↗

    PeptideScanner retained ClinicalTrials.gov record NCT01818752 at 2026-11-16T17:39:29.005Z. Its registry update date was 2019-08-26, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

Source year

2017

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT01302392↗

    PeptideScanner retained ClinicalTrials.gov record NCT01302392 at 2026-11-16T17:39:29.005Z. Its registry update date was 2017-05-02, and PeptideScanner's reviewed identity mapping was carfilzomib.↗

Source year

2014

1 record
  1. Regulatory

    Federal Register notice 2014-11175↗

    The Federal Register published notice 2014-11175, attributed to FDA and its parent HHS department, on 2014-05-15. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; KYPROLIS,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib.↗

Source year

2012

2 records
  1. Regulatory

    Drugs@FDA application NDA202714↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 202714 with status AP dated 2012-07-20, and names carfilzomib among the application record's active ingredients.↗

  2. Regulatory

    Federal Register notice 2012-10154↗

    The Federal Register published notice 2012-10154, attributed to FDA and its parent HHS department, on 2012-04-27. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib.↗